Servier Acquires Day One Biopharmaceuticals for $2.5 Billion to Strengthen Rare Oncology Portfolio
核心洞察
Servier announced a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion.
The acquisition positions Servier as a leader in pediatric low-grade glioma (搜索) and expands its oncology pipeline with programs ranging from early stage to phase 3.
The transaction represents a premium of approximately 68% over Day One's closing price on March 5, 2026, and is expected to close in the second quarter of 2026.
Servier, an independent international pharmaceutical group, has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction, announced on March 6, 2026, is expected to close in the second quarter of 2026 and positions Servier as a leader in pediatric low-grade glioma (搜索) while expanding its rare oncology portfolio.
Strategic Positioning in Rare Oncology
The acquisition reinforces Servier's position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. The deal strengthens Servier's portfolio and expands its oncology pipeline with programs ranging from early stage to phase 3, combining Day One's scientific expertise with Servier's established global capabilities.
"This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology," said Olivier Laureau, President of Servier. "It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer (搜索)."
Premium Valuation and Transaction Terms
Under the terms of the merger agreement, Servier will commence a cash tender offer to acquire all outstanding shares of Day One's common stock. The offer price represents a premium of approximately 68% over the closing price of Day One on March 5, 2026, and a premium of approximately 86% over the one-month volume weighted average price (VWAP) of Day One as of March 5, 2026.
Servier expects to fund the transaction through existing cash and investments. The consummation of the tender offer is subject to customary closing conditions, including the tender by Day One shareholders of at least a majority of the issued and outstanding shares and the receipt of U.S. antitrust clearance.
Day One's Strategic Value
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The company was founded to address the critical unmet need in pediatric cancer (搜索) therapeutic development.
"Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life threatening diseases," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma (搜索)."
Transaction Advisors and Next Steps
Goldman Sachs Bank Europe SE (搜索) is serving as exclusive financial advisor to Servier, with Baker McKenzie as legal counsel. Centerview Partners LLC (搜索) is serving as the exclusive financial advisor to Day One, with Fenwick & West LLP as legal counsel. Day One's Board of Directors recommends that shareholders tender their shares in the tender offer.
Upon successful completion of the tender offer, Servier will acquire any remaining shares through a second-step merger for the same consideration per share paid in the tender offer. The transaction remains subject to customary closing conditions and regulatory approvals.